Anavex Life Sciences Corp (AVXL)

[seventhwave]

THAT'S IT!!!
I'm sorry if this has been obvious to you guys ever since the PR (below) but "NEW" trial means dosing after 52 weeks is not bound by the trial protocol established for the past year and dosing can be optimized at this juncture AND IN ALL LIKELIHOOD WAS! That explains the inflection to the upside at 57 weeks and brings back memories of the 5 week readout which led to massive euphoria and the climb to $14. The good news this time though is that there should be no reason to expect a subsequent dip right after (17 weeks) and then stabilization, like we saw in 6-mo data, as they have all received some amount of A2-73 in the past.

The big question is HOW FAR UP does the line ramp to before stabilizing? We have six measured at roughly >=24 MMSE in the past. If a dozen more join them, heck, I'm calling this a cure and throwing a party! ('Normal' MMSE is defined as 24-30.)

NEW YORK, NY – March 10, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer’s trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety and efficacy data. The trial is independent of the Company’s planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer’s disease.

Hat-tip powerwalker for opening my eyes!

Going forward, when they show 1.5yr and 2 yr data, I hope they make it amply clear on the graphs that these are 2 different trials on the same set of patients or it will be misleading.